Utilization of cytoplasmic lysozyme immunoreactivity as a histiocytic marker in canine histiocytic disorders.

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Immunoreactive lysozyme was readily detectable in canine histiocytic disorders including systemic histiocytosis, malignant histiocytosis and granulomatous panniculitis. Lysozyme was less reliable as a histiocytic marker in cutaneous histiocytoma; forty percent of these tumors were negative for lysozyme expression. The marked heterogeneity in lysozyme expression in cutaneous histiocytoma may indicate that a proportion of these tumors show relatively primitive histiocytic differentiation and do not express lysozyme. Alternatively, this same proportion may exhibit a phenotype akin to cutaneous Langerhans cells which do not contain lysozyme. Lysozyme was not detectable in the tumor cells in lymphomatoid granulomatosis, atypical cutaneous histiocytoma, and histiocytic lymphosarcoma. Other evidence that these three disorders do not represent true histiocytic proliferative disorders is discussed.

Original languageEnglish (US)
Pages (from-to)757-762
Number of pages6
JournalVeterinary Pathology
Volume23
Issue number6
StatePublished - Nov 1986

Fingerprint

Muramidase
lysozyme
Canidae
Benign Fibrous Histiocytoma
dogs
histiocytosis
Lymphomatoid Granulomatosis
Histiocytic Sarcoma
Histiocytosis
Langerhans cells
Panniculitis
Neoplasms
lymphosarcoma
neoplasms
Langerhans Cells
Non-Hodgkin's Lymphoma
Phenotype
phenotype
Skin

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Utilization of cytoplasmic lysozyme immunoreactivity as a histiocytic marker in canine histiocytic disorders. / Moore, P. F.

In: Veterinary Pathology, Vol. 23, No. 6, 11.1986, p. 757-762.

Research output: Contribution to journalArticle

@article{38dc02661f4b4c7dbd01b235b2c97b77,
title = "Utilization of cytoplasmic lysozyme immunoreactivity as a histiocytic marker in canine histiocytic disorders.",
abstract = "Immunoreactive lysozyme was readily detectable in canine histiocytic disorders including systemic histiocytosis, malignant histiocytosis and granulomatous panniculitis. Lysozyme was less reliable as a histiocytic marker in cutaneous histiocytoma; forty percent of these tumors were negative for lysozyme expression. The marked heterogeneity in lysozyme expression in cutaneous histiocytoma may indicate that a proportion of these tumors show relatively primitive histiocytic differentiation and do not express lysozyme. Alternatively, this same proportion may exhibit a phenotype akin to cutaneous Langerhans cells which do not contain lysozyme. Lysozyme was not detectable in the tumor cells in lymphomatoid granulomatosis, atypical cutaneous histiocytoma, and histiocytic lymphosarcoma. Other evidence that these three disorders do not represent true histiocytic proliferative disorders is discussed.",
author = "Moore, {P. F.}",
year = "1986",
month = "11",
language = "English (US)",
volume = "23",
pages = "757--762",
journal = "Veterinary Pathology",
issn = "0300-9858",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Utilization of cytoplasmic lysozyme immunoreactivity as a histiocytic marker in canine histiocytic disorders.

AU - Moore, P. F.

PY - 1986/11

Y1 - 1986/11

N2 - Immunoreactive lysozyme was readily detectable in canine histiocytic disorders including systemic histiocytosis, malignant histiocytosis and granulomatous panniculitis. Lysozyme was less reliable as a histiocytic marker in cutaneous histiocytoma; forty percent of these tumors were negative for lysozyme expression. The marked heterogeneity in lysozyme expression in cutaneous histiocytoma may indicate that a proportion of these tumors show relatively primitive histiocytic differentiation and do not express lysozyme. Alternatively, this same proportion may exhibit a phenotype akin to cutaneous Langerhans cells which do not contain lysozyme. Lysozyme was not detectable in the tumor cells in lymphomatoid granulomatosis, atypical cutaneous histiocytoma, and histiocytic lymphosarcoma. Other evidence that these three disorders do not represent true histiocytic proliferative disorders is discussed.

AB - Immunoreactive lysozyme was readily detectable in canine histiocytic disorders including systemic histiocytosis, malignant histiocytosis and granulomatous panniculitis. Lysozyme was less reliable as a histiocytic marker in cutaneous histiocytoma; forty percent of these tumors were negative for lysozyme expression. The marked heterogeneity in lysozyme expression in cutaneous histiocytoma may indicate that a proportion of these tumors show relatively primitive histiocytic differentiation and do not express lysozyme. Alternatively, this same proportion may exhibit a phenotype akin to cutaneous Langerhans cells which do not contain lysozyme. Lysozyme was not detectable in the tumor cells in lymphomatoid granulomatosis, atypical cutaneous histiocytoma, and histiocytic lymphosarcoma. Other evidence that these three disorders do not represent true histiocytic proliferative disorders is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0022818490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022818490&partnerID=8YFLogxK

M3 - Article

C2 - 3027941

AN - SCOPUS:0022818490

VL - 23

SP - 757

EP - 762

JO - Veterinary Pathology

JF - Veterinary Pathology

SN - 0300-9858

IS - 6

ER -